FDA says COVID-19 boosters should be updated to combat two omicron subvariants


The Food and Drug Administration on Thursday told COVID-19 vaccine makers that plan to update their boosters to add a BA.4 and BA.5 spike protein component to the new shots that are in development. These “bivalent” boosters should equally target the two subvariants of omicron as well as the original strain of the virus and are expected to be rolled out to Americans in the fall or winter. Earlier this week, the FDA’s advisory committee on vaccines voted 19-2 that the COVID-19 boosters need to be modified to better combat omicron and its subvariants. The BA.4 and BA.5 subvariants now make up more than half of U.S. cases. The FDA said the primary series of shots will not be updated at this time. Moderna Inc., BioNTech SE BNTX, +5.01% and Pfizer Inc. PFE, +2.93%, and Novavax Inc. NVAX, -0.81% said this week that they plan to modify their COVID-19 boosters. Johnson & Johnson JNJ, +0.29% has no plans to modify its COVID-19 shot.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleKey Words: Liz Cheney calls Trump a ‘domestic threat,’ says GOP can’t be loyal to both him and the Constitution
Next articleBiden says he supports filibuster exception to codify Roe v. Wade


Please enter your comment!
Please enter your name here